People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy. Side effects for people who took both medications included nausea and ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.2 billion for Septerna, they said on Wednesday.

“I’m down about 50 pounds. I want to lose another 50,” Barkley said, revealing he gained 100 pounds after hip surgery. The target weight, he said, is 270 pounds. He said he is taking Zepbound, a prescription medication used for chronic weight management in adults with obesity or who are overweight.

Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— when used to treat overweight or obesity.